| Literature DB >> 34907908 |
Benjy Jy Tan1,2,3, Kenji Sugata1, Omnia Reda1,2,3,4, Misaki Matsuo1,2, Kyosuke Uchiyama5, Paola Miyazato2, Vincent Hahaut6,7, Makoto Yamagishi8, Kaoru Uchimaru8, Yutaka Suzuki9, Takamasa Ueno10, Hitoshi Suzushima11, Hiroo Katsuya2,12, Masahito Tokunaga13, Yoshikazu Uchiyama14, Hideaki Nakamura15, Eisaburo Sueoka16, Atae Utsunomiya13,17, Masahiro Ono2,18, Yorifumi Satou1,2.
Abstract
Human T cell leukemia virus type 1 (HTLV-1) mainly infects CD4+ T cells and induces chronic, persistent infection in infected individuals, with some developing adult T cell leukemia/lymphoma (ATL). HTLV-1 alters cellular differentiation, activation, and survival; however, it is unknown whether and how these changes contribute to the malignant transformation of infected cells. In this study, we used single-cell RNA-sequencing and T cell receptor-sequencing to investigate the differentiation and HTLV-1-mediated transformation of T cells. We analyzed 87,742 PBMCs from 12 infected and 3 uninfected individuals. Using multiple independent bioinformatics methods, we demonstrated the seamless transition of naive T cells into activated T cells, whereby HTLV-1-infected cells in an activated state further transformed into ATL cells, which are characterized as clonally expanded, highly activated T cells. Notably, the greater the activation state of ATL cells, the more they acquire Treg signatures. Intriguingly, the expression of HLA class II genes in HTLV-1-infected cells was uniquely induced by the viral protein Tax and further upregulated in ATL cells. Functional assays revealed that HTLV-1-infected cells upregulated HLA class II molecules and acted as tolerogenic antigen-presenting cells to induce anergy of antigen-specific T cells. In conclusion, our study revealed the in vivo mechanisms of HTLV-1-mediated transformation and immune escape at the single-cell level.Entities:
Keywords: Infectious disease; Leukemias; MHC class 2; T cells; Virology
Mesh:
Substances:
Year: 2021 PMID: 34907908 PMCID: PMC8670839 DOI: 10.1172/JCI150472
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 19.456